Skip to content

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02837705
Acronym
PRNP
Enrollment
213
Registered
2016-07-20
Start date
2015-09-01
Completion date
2019-03-01
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prion Diseases

Brief summary

The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.

Interventions

OTHERblood draw

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Relatives of patients of genetic Prion diseases * Obtained informed consent

Exclusion criteria

* No informed consent

Design outcomes

Primary

MeasureTime frame
Anti-Prion protein autoantibody levelsBaseline, up to 90 years

Countries

Austria, Germany, Israel, Italy, Slovakia, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026